Broad Institute Comprehensive Screening Center

布罗德研究所综合筛查中心

• 批准号: 7938954
• 负责人: STUART L SCHREIBER
• 金额: $ 1424.77万
• 依托单位: BROAD INSTITUTE, INC.
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-01 至 2014-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7938954
• 关键词: Broad; Institute; Comprehensive; Screening; Center

Biomedical researchers in the 21st century work in the epicenter of an explosion in the understanding of human disease. The complete sequences of relevant genomes, like the human and various infectious organisms, lay the foundation for the next steps in probing molecular mechanisms of disease. Broad Institute researchers recognized at an early stage of this revolution that the perturbation of the cellular pathways that underlie phenotypic changes with small molecules will make it possible to dissect cell circuitry and disease biology, thus enabling a path forward to correcting human diseases. We have operated a Screening Facility in a production mode over the past ten years in an open data-sharing environment, created the first comprehensive and public small-molecule database and analysis environment containing over 20 million binding and assay-well measurements, a novel chemical biology information model and many powerful analysis tools, and, in 2007, made a substantial investment in personnel, screening automation, LIMS and robotics that has substantially increased these already significant production capabilities. This screening facility resides within a rich environment focused on small molecules and small-molecule screening integrated with disease biology and genome biology. We propose here a plan to operate a Comprehensive Screening Center at the Broad Institute of Harvard and MIT (BCSC), leveraging and complementing existing organizational and infrastructure initiatives by collaborating with a wider MLPCN research community.

21 世纪的生物医学研究人员正处于对人类疾病的理解爆炸式增长的中心。相关基因组（如人类和各种传染性生物体）的完整序列为下一步探索疾病分子机制奠定了基础。博德研究所的研究人员在这场革命的早期阶段就认识到，小分子对表型变化背后的细胞途径的扰动将使剖析细胞回路和疾病生物学成为可能，从而为纠正人类疾病开辟一条道路。过去十年来，我们在开放数据共享环境中以生产模式运营筛选设施，创建了第一个综合性公共小分子数据库和分析环境，其中包含超过 2000 万个结合和测定孔测量结果、新颖的化学生物学信息模型和许多强大的分析工具，并于 2007 年在人员、筛选自动化、LIMS 和机器人技术方面进行了大量投资，大大提高了这些已经很重要的生产能力。该筛选设施位于一个丰富的环境中，专注于小分子以及与疾病生物学和基因组生物学相结合的小分子筛选。我们在此提出一项计划，在哈佛大学和麻省理工学院布罗德研究所 (BCSC) 运营一个综合筛查中心，通过与更广泛的 MLPCN 研究社区合作，利用和补充现有的组织和基础设施举措。